Should You Wear a CGM on a GLP-1? What the Evidence Shows

Over-the-counter glucose sensors arrived at the same moment GLP-1 drugs went mainstream, and the two get marketed together constantly: wear the sensor, watch your spikes flatten, prove the drug is working. The evidence is thinner than the marketing. Continuous glucose monitoring has strong, well-measured value in people with diabetes taking these drugs ^{[1] [2]}. In people without diabetes — which is most people taking a GLP-1 for weight — the research is early, the normal ranges are not agreed on, and the readings are easy to over-interpret ^{[3] [4]}. A CGM can be a useful feedback tool. It is not a measure of whether your GLP-1 is working.

The honest summary

• In diabetes, the CGM evidence on incretin drugs is real and quantified. Adding tirzepatide improved time-in-range by 9.0% at six months and 7.4% at twelve versus matched controls, with no increase in time below range and no severe hypoglycemia ^[1].
• In people without diabetes, there is no agreed normal. Reviews of sensor use outside diabetes note that reference ranges and clinically meaningful thresholds have not been established ^[3], so a reading you find alarming may be entirely ordinary.
• Glucose naturally varies a lot in healthy people. Work mining glycemic variability in non-diabetic adults found meaningful swings across waking and sleeping hours in people with no metabolic disease at all ^[4].
• Your GLP-1 is not judged by glucose if you do not have diabetes. The outcome that matters is weight, and the trials measure it directly ^[5]. A flat glucose curve is not the goal and a spiky one is not failure.
• Where a CGM genuinely helps is behavior. Seeing what a specific meal does to you is a useful feedback loop. Proposals to integrate monitoring with GLP-1 care lean on exactly that ^[2].

What the strongest study actually shows

The clearest CGM data on an incretin drug comes from a twelve-month study of adults with type 1 diabetes and excess weight who added tirzepatide off-label ^[1]. Sixty-one people on tirzepatide were compared with fifty-four matched controls. Time-in-range rose by 4.6% at three months and stayed higher at six, nine and twelve months, reaching +7.4% at a year. Mean glucose, time above range, time above 250 mg/dL and the coefficient of variation all fell. Half the tirzepatide group met the composite CGM target of time-in-range at or above 70% with time-below-range under 4%, against a quarter of controls.

Two things to hold onto. The first is that this is a retrospective, single-center case-control study in people with type 1 diabetes — the authors say plainly that proper randomized trials are needed ^[1]. The second is that it tells you what a GLP-1-class drug does to glucose in someone whose glucose is already dysregulated. It does not tell you what your sensor should look like if your pancreas works normally.

Why the non-diabetic evidence is weaker

A 2025 review of non-invasive and continuous monitoring in people without diabetes found the technology moving faster than the interpretive framework: sensors are accurate enough to be useful, but what counts as an abnormal excursion in someone with normal glucose tolerance is not settled ^[3]. That gap is the whole problem with consumer use. The device gives a precise number against an undefined standard.

Earlier work on glycemic variability in non-diabetic adults makes the same point from the other direction: the study set out to characterize normal variation across waking and sleeping periods and found substantial swings in people with no disease ^[4]. If you wear a sensor expecting a flat line, you will find something to worry about, because a flat line is not what normal physiology produces.

Where a CGM is genuinely useful on a GLP-1

There is a real case for monitoring, and a 2025 proposal for integrating continuous glucose monitoring into obesity management with GLP-1 drugs sets it out ^[2]: the sensor turns an abstract instruction (eat more protein, fewer refined carbohydrates) into immediate personal feedback. For people who respond to that kind of data, it can be a strong behavioral lever.

It is also genuinely important in one clinical situation: if you take insulin or a sulfonylurea alongside a GLP-1. Those drugs can cause hypoglycemia, GLP-1 drugs reduce how much of them you need, and a sensor with alarms is the appropriate tool. That is a medical indication, not a wellness purchase, and it should be set up with your prescriber.

Practical guidance

• If you have diabetes and take insulin or a sulfonylurea, a CGM is a clinical tool. Discuss it with your prescriber, especially while a GLP-1 dose is being increased.
• If you do not have diabetes, treat it as curiosity and feedback, not diagnosis. There is no agreed abnormal threshold for you ^[3].
• Do not judge your GLP-1 by the sensor. The drug is prescribed for weight; the trials measure weight ^[5].
• Watch for the restriction trap. Cutting foods to flatten a curve can undercut the protein and fiber intake that protects lean mass on a GLP-1.
• Take a low reading seriously only if you have symptoms or take a drug that causes hypoglycemia. Sensors read low in the interstitial fluid more often than blood truly is.